(Total Views: 559)
Posted On: 06/03/2021 5:27:44 PM
Post# of 145880
I would think near zero chance of approval given that population size. With a quick turnaround on phase 3 protocol and trial start, possible results by the end of November.
With the longhauler patient advocates well aware of leronlimab the phase 3 should fill extremely fast. With a positive p value those advocates will be quite strident with the FDA for quick approval.
With the longhauler patient advocates well aware of leronlimab the phase 3 should fill extremely fast. With a positive p value those advocates will be quite strident with the FDA for quick approval.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)